Sophion Bioscience receives new investment  

Existing investors put DKK 25 million into the Danish biotech company for commercialisation of its new drug discovery system QPatch 16

Copenhagen based Sophion Bioscience has received a DKK 25 million (USD 4.3 million) capital injection from its existing investors including NeuroSearch, SLS venture, Dansk Kapitalanlæg, Dansk Erhvervsinvestering and the Danish Fund for Industrial Growth. The sum will be used for the first phase of commercialising the company's ion-channel screening system QPatch 16 for drug discovery.


Sophion recently completed the development of QPatch 16 and the system will be externally tested by NeuroSearch and an international pharmaceutical company over the coming months. Sophion Bioscience was established in 2000 as a spin-off from NeuroSearch, on whose ion-channel technology platform QPatch is based. The news is reported by daily financial newspaper Børsen.


Link > Sophion Bioscience

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×